Back to top
more

OPKO Health (OPK)

(Delayed Data from NSDQ)

$1.51 USD

1.51
2,510,004

0.00 (0.00%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Invest in OPKO Health (OPK) Right Now

by Zacks Equity Research

OPKO Health's (OPK) flagship RAYALDEE lends it a competitive edge in the MedTech space.

Here's Why Investors Should Hold Patterson Companies Stock

by Zacks Equity Research

Patterson Companies (PDCO) gains from solid foothold in theAnimals Health business. However, the company is facing headwinds in the Dental segment.

Here's Why Investors Should Hold McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) gains traction from a solid foothold in the pharmaceutical and medical supplies distribution market. However, the company is grappled with regulatory constraints in Canada.

Cerner & Christiana Care Unite to Offer Bariatric Services

by Zacks Equity Research

Cerner (CERN) likely to gain from increased obesity rates in the United States.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining strength from the In Vitro Diagnostics (IVD) unit. The segment is a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.

Here's Why You Should Invest in Veeva Systems (VEEV) Now

by Zacks Equity Research

Veeva Systems' (VEEV) focus on cloud-based systems like Veeva Vault makes it a solid pick.

Masimo's (MASI) Preliminary Results for 2018 Cheer Investors

by Zacks Equity Research

Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.

Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results

by Zacks Equity Research

Intuitive Surgical (ISRG) is likely to gain from solid da Vinci contributions in fourth-quarter 2018.

Allscripts (MDRX) Collaborates With Microsoft, Shares Up

by Zacks Equity Research

Allscripts' (MDRX) Veradigm unit signs a memorandum of understanding with Microsoft to develop an integrated research model.

Luminex's (LMNX) Preliminary Q4 Results Cheer Investors

by Zacks Equity Research

Luminex (LMNX) likely to gain from strong segmental contributions in Q4.

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Exclusion of Varian Medical's (VAR) flagship Halcyon from Section 301 tariffs lends it a competitive edge in the MedTech space.

Abiomed's (ABMD) Preliminary Q3 Results Cheer Investors

by Zacks Equity Research

Abiomed (ABMD) raises its fiscal 2019 guidance. The company also expects to see strong contribution from its core Impella product line.

Here's Why Investors Should Hold Luminex (LMNX) Stock Now

by Zacks Equity Research

Luminex (LMNX) gains from strength in the Aries platform. However, cutthroat competition in the life sciences industry is worrisome.

Here's Why Investors Should Hold DENTSPLY (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY (XRAY) gains from strength in CAD/CAM dental imaging platform. However, sluggishness in the European business is worrisome.

Luminex Buys MilliporeSigma's Flow Cytometry Unit for $75M

by Zacks Equity Research

The recent buyout is likely to contribute $40-$50 million to Luminex's (LMNX) revenues in 2019.

Here's Why You Should Invest in PerkinElmer (PKI) Stock Now

by Zacks Equity Research

Focus on emerging markets, improving margins and encouraging guidance provide PerkinElmer (PKI) a competitive edge in the MedTech space.

Here's Why You Should Invest in Wright Medical (WMGI) Now

by Zacks Equity Research

A bullish outlook and a wide array of products make Wright Medical (WMGI) a promising investment pick.

Ecolab Inks Deal With Clearway for Renewable Power Project

by Zacks Equity Research

Ecolab's (ECL) virtual power purchase agreement with Clearway is part of a broader trend among corporate buyers. This will cover the company???s annual domestic energy use completely.

Here's Why Investors Should Retain CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED's (CNMD) steady focus on innovation is indicative of brighter prospects ahead. The company faces cutthroat competition in the niche space.

Becton, Dickinson's MAX Enteric Viral Panel Cleared by FDA

by Zacks Equity Research

Becton, Dickinson's (BDX) Diagnostic Systems portfolio lends it a competitive edge.

Here's Why You Should Buy Intuitive Surgical (ISRG) Now

by Zacks Equity Research

A solid outlook for 2018 and strength in robotics make Intuitive Surgical (ISRG) a promising investment pick.

Varian Medical's (VAR) Halcyon Excluded From Trade Tariffs

by Zacks Equity Research

Recent trade war-related talks are likely to favor Varian Medical (VAR) in the long run.

Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now

by Zacks Equity Research

Plethora of developments for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.

Integra Rides on Global Prospects, Hurt by Escalating Costs

by Zacks Equity Research

Integra LifeSciences (IART) aims at investment openings in the Asian market for a faster business boost than in the United States and also to flourish specific parts of its international businesses.

Quest Diagnostics (DGX) Divests India Business to Strand

by Zacks Equity Research

Quest Diagnostics (DGX) sees lucrative prospects in the U.S. diagnostic testing market.